Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

David McNeil

Psychiatry Buffalo Grove, IL Medical Doctor

NPI 1881652154 CMS profile 85009

135 N Arlington Heights Rd Ste 105, Buffalo Grove, IL 60089

Open in the dashboard

General payments

$13,033

434 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, David McNeil of Buffalo Grove, IL is reported in the CMS Open Payments database as having received $13,033 across 434 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $150 2
2023 General $1,264 56
2022 General $2,272 105
2021 General $2,272 123
2020 General $2,339 37
2019 General $4,738 111

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David McNeil
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to David McNeil were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year David McNeil Psychiatry median Middle half National median
2019 $4,738 $184 $59–$605 $163
2020 $2,339 $119 $36–$372 $114
2021 $2,272 $143 $43–$576 $132
2022 $2,272 $153 $50–$590 $149
2023 $1,264 $170 $56–$651 $160
2024 $150 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Allergan Inc. $5,240 33 payments
  2. Otsuka America Pharmaceutical, Inc. $1,037 53 payments
  3. Janssen Pharmaceuticals, Inc $733 47 payments
  4. Corium, Inc. $536 25 payments
  5. AbbVie, Inc. $487 40 payments
  6. Neos Therapeutics, LP $486 14 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $455 38 payments
  8. Sunovion Pharmaceuticals Inc. $451 22 payments
  9. Lundbeck LLC $426 29 payments
  10. Ironshore Pharmaceuticals Inc. $410 13 payments
  11. Other $2,770 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $8,073 431 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,960 3 payments
Products named General payments · program years 2019–2024
  1. VRAYLAR Neuroscience $5,240 33 payments
  2. REXULTI $761 48 payments
  3. INVEGA SUSTENNA $562 40 payments
  4. Azstarys $536 25 payments
  5. SPRAVATO $519 37 payments
  6. VRAYLAR Neuroscience $487 40 payments
  7. Adzenys XR-ODT $453 12 payments
  8. LATUDA $451 22 payments
  9. INVEGA TRINZA $394 28 payments
  10. AUSTEDO $333 12 payments
  11. Other $5,906 265 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

434 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record